Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US

 
• By Dave Wallace

Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.

Amgen
Amgen has launched two US biosimilars • Source: Shutterstock

More from Strategy

More from Business